ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 251 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,998 | -24.3% | 5,230,161 | -13.0% | 0.02% | -20.0% |
| Q2 2023 | $144,035 | +68.2% | 6,013,914 | +32.1% | 0.02% | +53.8% |
| Q1 2023 | $85,649 | +25.7% | 4,550,906 | +6.3% | 0.01% | +18.2% |
| Q4 2022 | $68,126 | -99.9% | 4,279,254 | -12.5% | 0.01% | -15.4% |
| Q3 2022 | $80,023,000 | +21.0% | 4,891,348 | +4.2% | 0.01% | +62.5% |
| Q2 2022 | $66,134,000 | -45.2% | 4,693,715 | -5.7% | 0.01% | -33.3% |
| Q1 2022 | $120,590,000 | -45.5% | 4,978,936 | -47.5% | 0.01% | -40.0% |
| Q4 2021 | $221,409,000 | +41.3% | 9,486,261 | +0.6% | 0.02% | +33.3% |
| Q3 2021 | $156,675,000 | -37.0% | 9,432,544 | -7.5% | 0.02% | -34.8% |
| Q2 2021 | $248,749,000 | +15.4% | 10,198,831 | +22.1% | 0.02% | +4.5% |
| Q1 2021 | $215,533,000 | -48.8% | 8,354,011 | +6.0% | 0.02% | -48.8% |
| Q4 2020 | $421,149,000 | -3.1% | 7,877,825 | -25.2% | 0.04% | -14.0% |
| Q3 2020 | $434,657,000 | -20.9% | 10,537,138 | -7.1% | 0.05% | -27.5% |
| Q2 2020 | $549,736,000 | +10.0% | 11,341,786 | -4.1% | 0.07% | -12.7% |
| Q1 2020 | $499,729,000 | -11.8% | 11,827,905 | -10.7% | 0.08% | +8.2% |
| Q4 2019 | $566,451,000 | +54.7% | 13,241,014 | +30.1% | 0.07% | +40.4% |
| Q3 2019 | $366,240,000 | +81.8% | 10,176,153 | +35.0% | 0.05% | +85.7% |
| Q2 2019 | $201,475,000 | +2.0% | 7,537,393 | +2.4% | 0.03% | -3.4% |
| Q1 2019 | $197,553,000 | +78.2% | 7,357,656 | +7.3% | 0.03% | +52.6% |
| Q4 2018 | $110,864,000 | +67.5% | 6,856,137 | +115.0% | 0.02% | +90.0% |
| Q3 2018 | $66,196,000 | +732.9% | 3,188,618 | +512.6% | 0.01% | +900.0% |
| Q2 2018 | $7,948,000 | -55.1% | 520,486 | -34.0% | 0.00% | -66.7% |
| Q1 2018 | $17,708,000 | -27.6% | 788,068 | -3.0% | 0.00% | -25.0% |
| Q4 2017 | $24,468,000 | -68.9% | 812,627 | -61.1% | 0.00% | -69.2% |
| Q3 2017 | $78,602,000 | -18.5% | 2,086,597 | -39.7% | 0.01% | -23.5% |
| Q2 2017 | $96,479,000 | -38.9% | 3,459,264 | -24.6% | 0.02% | -43.3% |
| Q1 2017 | $157,800,000 | -3.3% | 4,589,871 | -18.9% | 0.03% | -6.2% |
| Q4 2016 | $163,185,000 | -23.7% | 5,658,297 | -15.8% | 0.03% | -25.6% |
| Q3 2016 | $213,735,000 | -7.5% | 6,719,121 | -5.6% | 0.04% | -12.2% |
| Q2 2016 | $230,962,000 | +3.4% | 7,115,279 | -11.0% | 0.05% | +2.1% |
| Q1 2016 | $223,409,000 | +12.0% | 7,990,317 | +42.8% | 0.05% | +14.3% |
| Q4 2015 | $199,452,000 | +7.9% | 5,594,715 | +0.1% | 0.04% | +2.4% |
| Q3 2015 | $184,916,000 | -21.6% | 5,591,664 | -0.7% | 0.04% | -16.3% |
| Q2 2015 | $235,890,000 | +19.5% | 5,632,514 | -7.0% | 0.05% | +19.5% |
| Q1 2015 | $197,411,000 | -0.4% | 6,057,423 | -2.9% | 0.04% | -2.4% |
| Q4 2014 | $198,145,000 | +22.5% | 6,240,798 | -4.5% | 0.04% | +20.0% |
| Q3 2014 | $161,766,000 | +20.1% | 6,533,343 | +9.6% | 0.04% | +20.7% |
| Q2 2014 | $134,692,000 | +98.9% | 5,962,463 | +114.2% | 0.03% | +93.3% |
| Q1 2014 | $67,723,000 | -47.8% | 2,783,520 | -46.4% | 0.02% | 0.0% |
| Q4 2013 | $129,796,000 | +153.0% | 5,193,890 | +178.1% | 0.02% | +15.4% |
| Q3 2013 | $51,303,000 | +2.0% | 1,867,590 | -32.6% | 0.01% | +85.7% |
| Q2 2013 | $50,282,000 | – | 2,770,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |